RxDoctor Payments DataLook up a doctor →

Robert Wozniak, MD

Endocrinology, Diabetes & Metabolism · Rock Hill, SCNPI 1942282470

Payments from drug & device makers

$14,572in general payments, 2019–2025

Across 757 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Sanofi-aventis U.S. LLC$1K
  • Abbott$1K
  • Mannkind Corporation$866
  • Novo Nordisk$739
  • Corcept Therapeutics$720
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC111$1,773
Sanofi-aventis U.S. LLC67$1,281
Abbott62$1,169
Mannkind Corporation57$866
Novo Nordisk31$739
Corcept Therapeutics40$720
AstraZeneca38$657
Amgen(2 entities)32$632
Boehringer Ingelheim25$567
Bayer22$506
Amneal Pharmaceuticals LLC24$453
Merck22$377
Dexcom, Inc.24$375
Amarin Pharma, Inc.23$347
IBSA Pharma Inc.17$330
Echosens North America, Inc.1$293
Medtronic(2 entities)14$257
Insulet Corporation9$257
Cequr Corporation5$227
Amryt Pharma Holdings Ltd7$215
BETA Bionics, Inc.5$205
AbbVie13$188
Xeris Pharmaceuticals, Inc.10$175
Inspire Medical Systems, Inc.1$139
Ascendis Pharma Endocrinology Inc6$115
Recordati_rare_diseases_inc.5$114
Pfizer5$100
Tandem Diabetes Care, Inc.4$96
Ipsen Biopharmaceuticals, Inc3$81
Vistapharm, Inc.4$70
Takeda Pharmaceuticals U.S.A., Inc.3$69
Ultragenyx Pharmaceutical Inc.4$69
BD3$65
Ascensia Diabetes Care US Inc.2$61
Lifescan, Inc.4$60
Regeneron Healthcare Solutions, Inc.3$58
Neurocrine Biosciences, Inc.2$57
Renalytix AI, Inc.4$54
Chiesi USA, Inc.2$52
Nevro Corp.3$52
Tolmar, Inc.3$46
Esperion Therapeutics, Inc.3$46
Companion Medical, Inc.2$42
Johnson & Johnson3$41
Almatica Pharma LLC2$39
Antares Pharma, Inc.2$38
Clarus Therapeutics Inc.3$37
Aytu Biopharma, Inc.3$37
Embecta Corp.2$36
Amphastar Pharmaceuticals, Inc.2$34
Acerus Pharmaceuticals Corporation2$34
Novartis1$24
Globus Medical1$24
Rhythm Pharmaceuticals, Inc.1$22
Shire North American Group Inc1$21
Senseonics, Incorporated2$20
Madrigal Pharmaceuticals1$18
Vifor Pharma, Inc.1$17
Valeritas, Inc.1$17
GRT US Holding, Inc.1$17

How this compares

$14,572 in reported general payments places this provider in the 75th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024
$307,052
Medicare patients
716
Services billed
4,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Rock Hill

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →